Updated Asia-Pacific GERD Guideline

New recommendations on treating gastroesophageal reflux disease refractory to proton-pump inhibitor therapy and diagnosing Barrett esophagus

Sponsoring Organization: Asian Pacific Association of Gastroenterology

Target Audience: Gastroenterologists

Background and Objective: This is the third consensus-based guideline published since 2004 on management of gastroesophageal reflux disease (GERD) in the Asia-Pacific region. Specific topics include proton-pump inhibitor (PPI)-refractory GERD (rGERD) — defined as persistent and troublesome symptoms after standard-dose PPI therapy for ≥8 weeks — and screening and management of Barrett esophagus (BE).

What's Changed: The current guideline diverges from U.S. gastroenterological society guidelines in not requiring histologic confirmation of specialized columnar intestinal metaplasia to establish BE diagnosis and in excluding ultrashort BE <1…

Reviewing Author

David A. Johnson, MD

Disclosures

Consultant/Advisory boardMedscape/WebMD; Pfizer; CRH Medical Corporation; Aries

EquityCRH Medical Corporation

Editorial boardsMedscape Gastroenterology

Leadership positions in professional societiesAmerican College of Gastroenterology Research Institute Board of Directors